Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR) will participate in investor conferences including Barclays 26th Annual Global Healthcare Conference and H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. Fireside chats will be held on March 12 and March 26, 2024, respectively.
03/04/2024 - 08:00 AM
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Barclays 26th Annual Global Healthcare Conference
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com .
H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
About Vor Bio www.vorbio.com .
Contact: sspencer@vorbio.com
When is Vor Bio participating in the Barclays 26th Annual Global Healthcare Conference?
Vor Bio will participate in the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024 at 4:35 pm ET in Miami, FL.
Where can I watch the fireside chat from the Barclays conference?
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
When is the fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference?
The fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference will be on Tuesday, March 26, 2024 at 2:30 pm ET in a virtual location.
Vor Biopharma Inc
NASDAQ:VOR
VOR Rankings
#4827 Ranked by Stock Gains
VOR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About VOR
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar
